A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer
Standard
A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer. / Kind, Simon; Jaretzke, Annika; Büscheck, Franziska; Möller, Katharina; Dum, David; Höflmayer, Doris; Hinsch, Andrea; Weidemann, Sören; Fraune, Christoph; Möller-Koop, Christina; Hube-Magg, Claudia; Simon, Ronald; Wilczak, Waldemar; Lebok, Patrick; Witzel, Isabell; Müller, Volkmar; Schmalfeldt, Barbara; Paluchowski, Peter; Wilke, Christian; Heilenkötter, Uwe; von Leffern, Ingo; Krech, Till; Krech, Rainer H; von der Assen, Albert; Bawahab, Ahmed Abdulwahab; Burandt, Eike.
In: MOL CARCINOGEN, Vol. 58, No. 12, 12.2019, p. 2306-2315.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer
AU - Kind, Simon
AU - Jaretzke, Annika
AU - Büscheck, Franziska
AU - Möller, Katharina
AU - Dum, David
AU - Höflmayer, Doris
AU - Hinsch, Andrea
AU - Weidemann, Sören
AU - Fraune, Christoph
AU - Möller-Koop, Christina
AU - Hube-Magg, Claudia
AU - Simon, Ronald
AU - Wilczak, Waldemar
AU - Lebok, Patrick
AU - Witzel, Isabell
AU - Müller, Volkmar
AU - Schmalfeldt, Barbara
AU - Paluchowski, Peter
AU - Wilke, Christian
AU - Heilenkötter, Uwe
AU - von Leffern, Ingo
AU - Krech, Till
AU - Krech, Rainer H
AU - von der Assen, Albert
AU - Bawahab, Ahmed Abdulwahab
AU - Burandt, Eike
N1 - © 2019 The Authors. Molecular Carcinogenesis published by Wiley Periodicals, Inc.
PY - 2019/12
Y1 - 2019/12
N2 - Syndecan-1 (CD138) is a transmembrane proteoglycan expressed in normal and malignant tissues. It is of interest because of a possible prognostic effect in tumors and as a target for Indatuximab, a monoclonal antibody coupled to a cytotoxic agent. To assess the prognostic role of CD138 expression in breast cancer (BCa), a tissue microarray containing 1535 BCa specimens was analyzed by immunohistochemistry. Cytoplasmic, membranous, and stromal CD138 staining was separately analyzed. In normal breast tissue, CD138 staining was limited to epithelial cell membranes. In cancers, membranous staining tended to become weaker or even disappeared (38.3% of cancers with absence of membranous staining) but cytoplasmic and stromal staining newly appeared in 29.7% and 58.1% of cancers. Loss of membranous epithelial CD138 staining as well as presence of cytoplasmic and stromal CD138 positivity were-to a variable degree-associated with high pT, high grade, nodal metastasis, estrogen receptor-negative, progesterone receptor-negative, human epidermal growth factor receptor 2+, and poor overall patient survival. A combined analysis of epithelial and stromal CD138 expression revealed a link to overall patient survival (P < .0001) with best prognosis for patients with stromal positivity and absence of cytoplasmic staining, the worst prognosis for cancers with cytoplasmic staining and stromal negativity and intermediate prognosis for patients having either cytoplasmic staining or stromal negativity. In multivariate analyses, CD138 was not independent of established prognostic features. In summary, these data reveal a compartment depending prognostic effect of CD138 expression in BCa with cytoplasmic positivity being linked to aggressive cancer and stromal CD138 being linked to a more favorable prognosis.
AB - Syndecan-1 (CD138) is a transmembrane proteoglycan expressed in normal and malignant tissues. It is of interest because of a possible prognostic effect in tumors and as a target for Indatuximab, a monoclonal antibody coupled to a cytotoxic agent. To assess the prognostic role of CD138 expression in breast cancer (BCa), a tissue microarray containing 1535 BCa specimens was analyzed by immunohistochemistry. Cytoplasmic, membranous, and stromal CD138 staining was separately analyzed. In normal breast tissue, CD138 staining was limited to epithelial cell membranes. In cancers, membranous staining tended to become weaker or even disappeared (38.3% of cancers with absence of membranous staining) but cytoplasmic and stromal staining newly appeared in 29.7% and 58.1% of cancers. Loss of membranous epithelial CD138 staining as well as presence of cytoplasmic and stromal CD138 positivity were-to a variable degree-associated with high pT, high grade, nodal metastasis, estrogen receptor-negative, progesterone receptor-negative, human epidermal growth factor receptor 2+, and poor overall patient survival. A combined analysis of epithelial and stromal CD138 expression revealed a link to overall patient survival (P < .0001) with best prognosis for patients with stromal positivity and absence of cytoplasmic staining, the worst prognosis for cancers with cytoplasmic staining and stromal negativity and intermediate prognosis for patients having either cytoplasmic staining or stromal negativity. In multivariate analyses, CD138 was not independent of established prognostic features. In summary, these data reveal a compartment depending prognostic effect of CD138 expression in BCa with cytoplasmic positivity being linked to aggressive cancer and stromal CD138 being linked to a more favorable prognosis.
U2 - 10.1002/mc.23119
DO - 10.1002/mc.23119
M3 - SCORING: Journal article
C2 - 31545001
VL - 58
SP - 2306
EP - 2315
JO - MOL CARCINOGEN
JF - MOL CARCINOGEN
SN - 0899-1987
IS - 12
ER -
